Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 184

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy

Open access
Kong, Dexin, Yamori, Takao · 2008 · Cancer Science

Abstract

Phosphatidylinositol 3‐kinases (PI3K) are a group of lipid kinases that phosphorylate phosphoinositides at the 3‐hydroxyl group of the inositol ring to generate phosphatidylinositol 3,4,5‐trisphosphate, a second messenger with key roles in fundamental cellular responses such as cell proliferation and metabolism. Frequent mutations found in or amplification of the PIK3CA gene and loss of phosphatase and tensin homolog deleted on chromosome 10 function in human tumors suggest that PI3K is a potential target for cancer therapy. During the last 5 years, several specific PI3K inhibitors were developed that were directed against various diseases. Some of them revealed potent anticancer efficacy and are now undergoing clinical trials. Some PI3K inhibitors showed antiangiogenic effects. Combined use of PI3K inhibitors with other chemotherapeutic agents or with radiotherapy produced synergistic therapeutic efficacies in treating cancer and showed reduced side effects. The rapid progress made in developing novel PI3K inhibitors in recent years promises bright prospects for finding a PI3K‐targeted anticancer drug in the near future. (Cancer Sci 2008; 99: 1734–1740)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1349-7006.2008.00891.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 89

  1. 10.1038/42648 · DOI · Paper page
  2. 10.1016/S0968-0004(97)01061-X · DOI · Paper page
  3. 10.1038/332644a0 · DOI · Paper page
  4. 10.1016/S0092-8674(00)81883-8 · DOI · Paper page
  5. 10.1016/S1357-2725(02)00270-4 · DOI
  6. 10.1016/S1357-4310(00)01770-6 · DOI · Paper page
  7. 10.1016/j.ctrv.2003.07.007 · DOI · Paper page
  8. 10.1016/S0005-2760(98)00139-8 · DOI · Paper page
  9. 10.1034/j.1600-0854.2002.30605.x · DOI · Paper page
  10. 10.1038/12075 · DOI · Paper page
  11. 10.1038/nrd1902 · DOI · Paper page
  12. 10.1016/j.tibs.2005.02.008 · DOI · Paper page
  13. 10.1074/jbc.272.31.19236 · DOI · Paper page
  14. 10.1073/pnas.94.9.4330 · DOI · Paper page
  15. 10.1126/science.1096502 · DOI · Paper page
  16. 10.1158/1078-0432.CCR-04-2142 · DOI · Paper page
  17. 10.1016/j.bbrc.2005.12.025 · DOI
  18. 10.1016/j.cell.2006.03.035 · DOI · Paper page
  19. 10.1038/nm1232 · DOI · Paper page
  20. 10.1126/science.287.5455.1049 · DOI · Paper page
  21. 10.1126/science.287.5455.1046 · DOI · Paper page
  22. 10.1126/science.287.5455.1040 · DOI · Paper page
  23. 10.1038/nm1291 · DOI · Paper page
  24. 10.1038/nm1284 · DOI · Paper page
  25. 10.4049/jimmunol.170.5.2647 · DOI · Paper page
  26. 10.1038/nature02369 · DOI · Paper page
  27. 10.2174/156652405774641034 · doi:10.2174/156652405774641034
  28. 10.1074/jbc.M404097200 · DOI · Paper page
  29. 10.1083/jcb.200403069 · DOI · Paper page
  30. 10.1016/j.ccr.2005.08.008 · DOI · Paper page
  31. 10.1016/j.ccr.2006.05.002 · doi:10.1016/j.ccr.2006.05.002
  32. 10.1158/0008-5472.CAN-05-0917 · DOI · Paper page
  33. 10.1038/46319 · DOI · Paper page
  34. 10.1016/S1097-2765(05)00089-4 · DOI · Paper page
  35. 10.1016/S0006-291X(84)80264-8 · DOI
  36. 10.1016/0006-291X(85)91761-9 · DOI
  37. 10.1016/0006-291X(83)91220-2 · DOI
  38. 10.1016/0006-2952(82)90028-4 · DOI
  39. 10.1111/j.1432-1033.1983.tb07692.x · DOI · Paper page
  40. 10.1016/S0021-9258(17)37680-9 · DOI · Paper page
  41. 10.1042/bj3510095 · DOI · Paper page
  42. Hu L, 2000, In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3‐kinase inhibitor (LY294002), Clin Cancer Res, 6, 880
  43. 10.1016/S0007-1536(57)80033-3 · doi:10.1016/s0007-1536(57)80033-3
  44. 10.1039/c39720001061 · doi:10.1039/c39720001061
  45. 10.1007/BF01927691 · DOI
  46. Powis G, 1994, Wortmannin, a potent and selective inhibitor of phosphatidylinositol‐3‐kinase, Cancer Res, 54, 2419
  47. 10.1016/S0021-9258(17)41900-4 · DOI · Paper page
  48. 10.1042/bj2960297 · DOI · Paper page
  49. 10.1016/S0021-9258(18)45857-7 · DOI · Paper page
  50. 10.1128/MCB.16.4.1722 · DOI · Paper page
  51. Ihle NT, 2004, Molecular pharmacology and antitumor activity of PX‐866, a novel inhibitor of phosphoinositide‐3‐kinase signaling, Mol Cancer Ther, 3, 763, 10.1158/1535-7163.763.3.7 · DOI · Paper page
  52. 10.1158/1535-7163.MCT-05-0149 · DOI
  53. 10.1182/blood-2003-05-1667 · DOI · Paper page
  54. 10.1096/fj.05-5045com · DOI · Paper page
  55. 10.1182/blood-2004-08-3225 · DOI · Paper page
  56. 10.1038/sj.onc.1209670 · DOI
  57. 10.1073/pnas.0606956103 · DOI
  58. 10.1016/j.ccr.2006.03.029 · DOI · Paper page
  59. 10.1158/0008-5472.CAN-07-2154 · DOI · Paper page
  60. 10.1158/0008-5472.CAN-06-4615 · DOI · Paper page
  61. Stauffer FG‐EC, 2007, Proceedings of American Association for Cancer Research
  62. 10.1158/0008-5472.CAN-07-0669 · DOI · Paper page
  63. 10.1093/jnci/djj133 · DOI · Paper page
  64. 10.1111/j.1349-7006.2007.00580.x · DOI · Paper page
  65. 10.1002/jcp.20707 · DOI
  66. 10.1073/pnas.081063798 · DOI · Paper page
  67. 10.1074/jbc.M110219200 · DOI · Paper page
  68. 10.1159/000046610 · DOI · Paper page
  69. Jiang BH, 2001, Phosphatidylinositol 3‐kinase signaling controls levels of hypoxia‐inducible factor 1, Cell Growth Differ, 12, 363
  70. 10.1038/ncb1695 · DOI · Paper page
  71. 10.1016/j.devcel.2005.08.001 · DOI · Paper page
  72. 10.1073/pnas.040560897 · DOI · Paper page
  73. 10.1016/j.cellsig.2007.07.025 · DOI · Paper page
  74. Su JD, 2003, PTEN and phosphatidylinositol 3′‐kinase inhibitors up‐regulate p53 and block tumor‐induced angiogenesis: evidence for an effect on the tumor and endothelial compartment, Cancer Res, 63, 3585
  75. Hu L, 2002, Inhibition of phosphatidylinositol 3′‐kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models, Cancer Res, 62, 1087
  76. Asselin E, 2001, XIAP regulates Akt activity and caspase‐3‐dependent cleavage during cisplatin‐induced apoptosis in human ovarian epithelial cancer cells, Cancer Res, 61, 1862
  77. 10.1182/blood.V86.2.726.bloodjournal862726 · DOI · Paper page
  78. 10.1182/blood-2002-11-3429 · DOI · Paper page
  79. 10.1038/sj.onc.1205724 · DOI
  80. 10.1182/blood-2007-09-114454 · DOI
  81. 10.1016/j.ctrv.2006.01.003 · DOI · Paper page
  82. 10.1007/s00401-005-1001-0 · DOI
  83. Fan QW, 2003, Combinatorial efficacy achieved through two‐point blockade within a signaling pathway – a chemical genetic approach, Cancer Res, 63, 8930
  84. Sarkaria JN, 1998, Inhibition of phosphoinositide 3‐kinase related kinases by the radiosensitizing agent wortmannin, Cancer Res, 58, 4375
  85. Rosenzweig KE, 1997, Radiosensitization of human tumor cells by the phosphatidylinositol3‐kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA‐dependent protein kinase and prolonged G2–M delay, Clin Cancer Res, 3, 1149
  86. 10.1073/pnas.0510772103 · DOI · Paper page
  87. 10.1158/0008-5472.CAN-05-0152 · DOI
  88. 10.1126/science.7701324 · DOI · Paper page
  89. 10.1038/sj.onc.1207115 · DOI · Paper page

Cited by

See all 184

Metadata

Authors
Kong, D., & Yamori, T.
Venue
Cancer Science
Publisher
Wiley
Published
2008-08-21
Volume
99
Issue
9
Pages
1734-1740
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2088118561
Cited by
184
References
7
FWCI
6.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy. https://app.cochat.ai/papers/10.1111/j.1349-7006.2008.00891.x
The paper
Kong, D., & Yamori, T. (2008). Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy. Cancer Science. https://doi.org/10.1111/j.1349-7006.2008.00891.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.